01—Abstract
Summary
Summary of the 10-K filed February 27, 2009. Cited figures are marked; the original filing is the authoritative source.
Eli Lilly and Company's 2008 10-K filing reveals a challenging year marked by significant acquisition-related charges and legal settlements, which resulted in a net loss of $2.07 billiona.
Despite these headwinds, the company demonstrated resilience with a 9% increase in worldwide sales to $20.38 billionb, driven by strong performance in key products like Cymbalta, Cialis, and Alimta. The acquisition of ImClone Systems for $6.5 billion significantly expanded Lilly's oncology portfolio and biotechnology capabilities, albeit with a substantial $4.69 billion charge for acquired in-process research and development. Of critical importance to investors are the substantial charges impacting the bottom line, primarily stemming from the ImClone acquisition and a $1.48 billion charge to resolve investigations into Zyprexa's marketing practices.
These items overshadowed otherwise solid operational performance. The company also faces ongoing patent challenges and regulatory scrutiny, particularly concerning Zyprexa and other major products, which could impact future revenues and profitability. However, Lilly maintains a strong financial position with robust operating cash flow and a growing dividend, indicating management's confidence in its future prospects.
02—Key points
Key Highlights
- Worldwide sales grew 9% to $20.38 billion in 2008, driven by strong volume increases in key products.
- The company reported a net loss of $2.07 billion in 2008, significantly impacted by a $4.69 billion charge for acquired in-process R&D related to the ImClone acquisition and a $1.48 billion charge for Zyprexa investigation settlements.
- Acquisition of ImClone Systems for $6.5 billion bolstered the company's oncology pipeline and biotechnology capabilities.
- Key products like Cymbalta, Cialis, and Alimta showed significant sales growth, offsetting declines in other areas.
- Eli Lilly is actively defending against patent challenges for several key products, including Cymbalta, Gemzar, Alimta, Evista, and Zyprexa, with potential material adverse impacts if unfavorable outcomes occur.
- The company continues to face regulatory scrutiny and legal challenges, particularly related to past marketing and promotional practices, with substantial charges recorded.
- Despite the net loss, Eli Lilly demonstrated continued financial strength with strong operating cash flow and maintained its track record of increasing dividends.
03—One dollar
04—Financials
Financial Highlights
Figures from 10-KFY2008filed February 27, 2009Financial Statements
FY2008 against FY2007
| Line item | FY2008FY2007 | Change |
|---|---|---|
| Revenue | $20.37B$18.63B | +9.3% |
| Cost of Revenue | $4.38B$4.25B | +3.0% |
| Gross Profit | $16.00B$14.38B | +11.2% |
| R&D Expenses | $3.84B$3.49B | +10.2% |
| SG&A Expenses | $6.63B$6.10B | +8.7% |
| Interest Expense | -$228.30M— | — |
| Net Income | -$2.07B$2.95B | −170.2% |
| EPS (Basic) | $-1.89— | — |
| EPS (Diluted) | $-1.89— | — |
| Shares Outstanding (Basic) | 1.09B— | — |
| Shares Outstanding (Diluted) | 1.09B— | — |
05—Questions
Frequently Asked Questions
What was the primary driver for the net loss in 2008?
The primary driver for the net loss of $2.07 billion in 2008 was the impact of significant charges related to the acquisition of ImClone Systems, which included a $4.69 billion charge for acquired in-process research and development, and a $1.48 billion charge to resolve investigations into the marketing practices of Zyprexa.
How did the acquisition of ImClone Systems affect Eli Lilly's business?
The acquisition of ImClone Systems for $6.5 billion significantly expanded Eli Lilly's oncology portfolio and strengthened its biotechnology capabilities. It brought targeted therapies, oncolytic agents, and a robust oncology pipeline across all phases of clinical development.
What are the main risks and challenges facing Eli Lilly based on this filing?
Key risks include ongoing patent challenges from generic manufacturers for major products, regulatory scrutiny and potential legal ramifications from past marketing practices, and the high cost and uncertainty associated with pharmaceutical research and development. Additionally, the company is subject to pricing pressures from government entities and payers, and potential impacts from economic downturns on healthcare spending.
Which products were the main sales drivers in 2008?
The main sales drivers in 2008 were Cymbalta, Cialis, and Alimta, which showed significant year-over-year sales growth. Other notable contributors included Humalog and Gemzar.
06—Continue